bioAffinity Stock (NASDAQ:BIAF)
Previous Close
$1.52
52W Range
$0.69 - $13.80
50D Avg
$2.35
200D Avg
$2.54
Market Cap
$7.39M
Avg Vol (3M)
$8.28M
Beta
-1.33
Div Yield
-
BIAF Company Profile
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.